3 completed. 2 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow BCN Peptides: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients APVAC1 vaccine plus Poly-ICLC and GM-CSF, APVAC2 vaccine plus Poly-ICLC and GM-CSF - Glioblastoma | Phase 1 | Completed | Immatics Biotechnologies GmbH | 16 | 2014-10-01 | 2018-08-07 |
| Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy COLIRIOBCN070660, Placebo, Brimonidine - Diabetic Retinopathy | Phase 2 / Phase 3 | Completed | BCN Peptides | 450 | 2013-02-01 | 2016-01-12 |
| A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm Acetyl-Hexapeptide Topical Treatment, placebo - Focal Dystonia | Phase 1 / Phase 2 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 24 | 2009-07-01 | 2012-09-06 |
Blepharospasm (1) · Diabetic Retinopathy (1) · Dystonia (1) · Dystonic Disorders (1) · Glioblastoma (1)
Brimonidine Tartrate (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · poly ICLC (1) · sargramostim (1)
Denmark (2) · Germany (2) · Spain (2) · France (1) · Italy (1) · Netherlands (1) · Portugal (1) · Switzerland (1) · United Kingdom (1) · United States (1)
Pierre-Yves Dietrich, Professor (1) · Wolfgang Wick, Professor (1)